Literature DB >> 69297

The development of mexiletine in the management of ventricular dysrhythmias.

N P Campbell, N C Chaturvedi, R G Shanks, J G Kelly, J E Strong, A A Adgey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 69297

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  7 in total

Review 1.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 2.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

3.  Mexiletine in normal volunteers.

Authors:  N P Campbell; J G Kelly; A A Adgey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

Review 4.  Adverse effects of antiarrhythmic drugs.

Authors:  J B Schwartz; D Keefe; D C Harrison
Journal:  Drugs       Date:  1981-01       Impact factor: 9.546

5.  Mexiletine for ventricular arrhythmia after repair of tetralogy of Fallot.

Authors:  I D Malcolm; D Stubington; J E Gibbons
Journal:  Can Med Assoc J       Date:  1980-09-20       Impact factor: 8.262

6.  Observations on haemodynamic effects of mexiletine.

Authors:  N P Campbell; S A Zaidi; A A Adgey; G C Patterson; J F Pantridge
Journal:  Br Heart J       Date:  1979-02

7.  Cirrhosis of the liver markedly impairs the elimination of mexiletine.

Authors:  P J Pentikäinen; S Hietakorpi; M O Halinen; L M Lampinen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.